Immunoregulatory Dendritic Lipopeptide Nanoparticles for High-Capacity Cisplatin Delivery and Pancreatic Cancer Chemo-Immunotherapy.

Authors

Xiuli Zheng, Xulei Wang, Qiyi Feng, Lei Jiang

Published in

ACS applied materials & interfaces. Jul 13, 2026. Epub Jul 13, 2026.

Abstract

Lipid nanoparticles (LNPs) are promising for cisplatin delivery but are hindered by low drug loading, instability, and poor efficacy. Here, multicarboxyl dendritic lipopeptides were developed to enhance cisplatin loading via platinum coordination and improve tumor targeting. Structure-activity relationship studies identified DG3 as the optimal lipopeptide, enabling high drug-loading LNPs (hDDLN) with good stability and delivery efficiency. Pt/hDDLN showed a superior therapeutic index over conventional liposomes in vitro and in vivo. Combining Pt/hDDLN with the stimulator of interferon genes (STING) agonists synergistically enhanced immunotherapy by promoting cytotoxic T lymphocyte (CTL) infiltration, dendritic cell (DC) maturation, and reducing Regulatory T cell (Treg). Mechanistically, hDDLN activated DCs via the inducible nitric oxide synthase-cyclic guanosine monophosphate-phosphorylated myosin light chain (iNOS-cGMP-pMLC) pathway, boosting pro-inflammatory responses. This coordination-driven strategy advances LNP-based cisplatin delivery for chemo-immunotherapy of malignancies.

PMID:
42444257
Bibliographic data and abstract were imported from PubMed on 14 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.